Israeli real-world data shows vaccine is 97% effective

March 14, 2021 by JNS
Read on for article

The Israeli Ministry of Health, Pfizer and BioNTech said on Thursday that data from Israel’s national vaccination campaign demonstrates that their vaccine is 94% effective in preventing asymptomatic infections.

Pfizer’s COVID-19 vaccine on the production line. Credit: Mike Mareen/Shutterstock

They also said that Israeli data shows that vaccinations prevented symptomatic disease, severe cases and death with 97% effectiveness, according to a statement released by the companies and the Health Ministry.

More than 5 million Israelis, or about 55% of its population of 9 million people, have received the first shot of the vaccine, and nearly 4 four million, or 43%, have gotten the second shot.

The analysis was derived from data collected by Israel’s Health Ministry from Jan. 17 until March 6.

“Israel’s strong health system and an unprecedented societal mobilization and awareness allowed us to achieve high national uptake of the COVID-19 vaccine in a short period of time. Thanks to our comprehensive public-health surveillance program, we have been able to document the remarkable success of the nationwide vaccination campaign with the COVID-19 vaccine,” said Professor Yeheskel Levy, director of Israel’s Ministry of Health.

He added: “Incidence rates in the fully vaccinated population have massively dropped compared to the unvaccinated population, showing a marked decline in hospitalized cases due to COVID-19.”

JNS

Speak Your Mind

Comments received without a full name will not be considered
Email addresses are NEVER published! All comments are moderated. J-Wire will publish considered comments by people who provide a real name and email address. Comments that are abusive, rude, defamatory or which contain offensive language will not be published

Got something to say about this?

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Discover more from J-Wire

Subscribe now to keep reading and get access to the full archive.

Continue reading